About Smilow Cancer Hospital & Yale Cancer Center
The Smilow Cancer Hospital at Yale New Haven is one of the nation’s pre-eminent cancer hospitals, Connecticut’s largest provider of cancer care and the only comprehensive cancer facility in the Northeast – bringing together both inpatient and outpatient care in one hospital.
In addition to the flagship Smilow Cancer Hospital in New Haven, Smilow offers state-of-the-art cancer services at several convenient locations throughout the region – including Greenwich.
The Yale Cancer Center
Partnering with the Yale Cancer Center, the Smilow Cancer Hospital offers the very latest care, delivered by some of the nation’s most prominent and highly respected physicians and nurses. A leader in ground-breaking academic medicine, Smilow offers more than 300 open clinical trials – bringing innovation and new hope to patients each year, including access to Phase I trials.
Research Excellence at Yale Cancer Center – Facts and Figures
- Celebrating 47 years as Connecticut’s only comprehensive cancer center by the National Cancer Institute
- Over 300 cancer researchers on faculty
- Four FDA drug approvals stemming from YCC clinical trials since 2019
- 462,886 square feet of research space
- #13 in National Institutes of Health funding
- #14 in National Cancer Institute funding
- $99 million in cancer research funding
- $31 million in funding from the National Cancer Institute
- 96 National Cancer Institute funded projects
- 16 members of the National Academy of Sciences
- 16 members of the National Academy of Medicine
- 11 Howard Hughes Medical Investigators
- 5414 cancer research publications; 1269 in high impact journals (July 2012-July 2020)
Patient Care at Smilow Cancer Hospital
- Treating nearly half of the 20,000 patients diagnosed with cancer annually in Connecticut
- 13 multidisciplinary cancer programs
- 168 inpatient beds, 12 operating rooms, 100 infusion chairs
- 400 oncology nurses on staff
- 377,442 square feet of clinical space
- More than 300 open clinical trials providing the most advanced cancer therapies, including a state-of-the-art Phase I Clinical Trials Infusion Unit for patients on phase I trials.